News from eli lilly and company; boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

The European Commission (EC) granted marketing authorisation for Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim's insulin glargine...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 18, 2014, 17:32 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

 The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

Jun 16, 2014, 11:45 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Type 2 diabetes: Investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials

Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were...

Jun 15, 2014, 15:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials

 Two phase III clinical trials found  the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels...

Jun 14, 2014, 13:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®

For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the...

Jun 09, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 43 Presentations at the 74th American Diabetes Association Scientific Sessions®

 More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly...

May 23, 2014, 06:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe

The European Commission granted marketing authorization for Jardiance® (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2)...

May 15, 2014, 12:45 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed...

Apr 14, 2014, 09:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration...

Mar 21, 2014, 08:25 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Empagliflozin for Approval to Reduce Blood Sugar Levels in Adults with Type 2 Diabetes in Europe

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced a positive opinion from the Committee for...

Mar 05, 2014, 09:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug...

Dec 20, 2013, 14:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

 Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the...

Dec 02, 2013, 10:47 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation

 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate...

Sep 24, 2013, 06:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes

 Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced results from two post-hoc, pooled analyses of data from...